2.05
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Cleveland BioLabs Inc | CBLI | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 2.05 | 0.00 | 0.00 | 0.00 | 2.05 | 20:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 1.97 | 2.10 | 0.13 | 6.19% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 2.05 | USD |
Cleveland BioLabs Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 23.38M | 11.40M | 7.74M | $ 1.11M | $ - | -0.23 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | 32.10% |
Cleveland BioLabs News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CBLI Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.13 | 2.25 | 1.94 | 2.01 | 53,047 | -0.08 | -3.76% |
| 1 Month | 1.70 | 2.60 | 1.61 | 2.08 | 187,270 | 0.35 | 20.59% |
| 3 Months | 3.69 | 4.00 | 1.27 | 2.09 | 213,724 | -1.64 | -44.44% |
| 6 Months | 0.97 | 5.10 | 0.515 | 3.12 | 591,668 | 1.08 | 111.34% |
| 1 Year | 1.47 | 5.10 | 0.50 | 3.05 | 307,622 | 0.58 | 39.46% |
| 3 Years | 3.95 | 5.10 | 0.50 | 3.01 | 120,873 | -1.90 | -48.1% |
| 5 Years | 2.78 | 7.24 | 0.50 | 3.85 | 181,754 | -0.73 | -26.26% |
Cleveland BioLabs Description
| Cleveland BioLabs Inc is a biopharmaceutical company. The company is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of Toll-like immune receptor activators has applications in the mitigation of radiation injury and immuno-oncology. Its lead product candidate is entolimod, an immuno-stimulatory agent, which is developed as a radiation countermeasure and immunotherapy for oncology and other indications. Entolimod is a Toll-like receptor 5 (TLR5) agonist, which is developed as a radiation countermeasure for prevention of death from Acute Radiation Syndrome (ARS), and as an oncology drug. |
